Browse KDR

Summary
SymbolKDR
Namekinase insert domain receptor
Aliases FLK1; VEGFR; VEGFR2; CD309; vascular endothelial growth factor receptor 2; fetal liver kinase 1; kinase inse ......
Chromosomal Location4q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell junction Endoplasmic reticulum Note=Localized with RAP1A at cell-cell junctions (By similarity). Colocalizes with ERN1 and XBP1 in the endoplasmic reticulum in endothelial cells in a vascular endothelial growth factor (VEGF)-dependent manner (PubMed:23529610). ; SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I membrane protein. Cytoplasm. Nucleus. Cytoplasmic vesicle. Early endosome. Note=Detected on caveolae-enriched lipid rafts at the cell surface. Is recycled from the plasma membrane to endosomes and back again. Phosphorylation triggered by VEGFA binding promotes internalization and subsequent degradation. VEGFA binding triggers internalization and translocation to the nucleus.; SUBCELLULAR LOCATION: Isoform 2: Secreted ; SUBCELLULAR LOCATION: Isoform 3: Secreted.
Domain PF07679 Immunoglobulin I-set domain
PF00047 Immunoglobulin domain
PF07714 Protein tyrosine kinase
Function

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

> Gene Ontology
 
Biological Process GO:0000266 mitochondrial fission
GO:0001525 angiogenesis
GO:0001570 vasculogenesis
GO:0001667 ameboidal-type cell migration
GO:0001935 endothelial cell proliferation
GO:0001936 regulation of endothelial cell proliferation
GO:0001938 positive regulation of endothelial cell proliferation
GO:0001952 regulation of cell-matrix adhesion
GO:0001954 positive regulation of cell-matrix adhesion
GO:0002040 sprouting angiogenesis
GO:0002042 cell migration involved in sprouting angiogenesis
GO:0003158 endothelium development
GO:0003254 regulation of membrane depolarization
GO:0006914 autophagy
GO:0007044 cell-substrate junction assembly
GO:0007045 cell-substrate adherens junction assembly
GO:0007160 cell-matrix adhesion
GO:0008360 regulation of cell shape
GO:0010506 regulation of autophagy
GO:0010508 positive regulation of autophagy
GO:0010594 regulation of endothelial cell migration
GO:0010595 positive regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010634 positive regulation of epithelial cell migration
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0010821 regulation of mitochondrion organization
GO:0010822 positive regulation of mitochondrion organization
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling
GO:0016236 macroautophagy
GO:0016239 positive regulation of macroautophagy
GO:0016241 regulation of macroautophagy
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019722 calcium-mediated signaling
GO:0019932 second-messenger-mediated signaling
GO:0022604 regulation of cell morphogenesis
GO:0030198 extracellular matrix organization
GO:0030335 positive regulation of cell migration
GO:0031589 cell-substrate adhesion
GO:0032103 positive regulation of response to external stimulus
GO:0032844 regulation of homeostatic process
GO:0034329 cell junction assembly
GO:0034330 cell junction organization
GO:0034332 adherens junction organization
GO:0034333 adherens junction assembly
GO:0035162 embryonic hemopoiesis
GO:0035584 calcium-mediated signaling using intracellular calcium source
GO:0035767 endothelial cell chemotaxis
GO:0035924 cellular response to vascular endothelial growth factor stimulus
GO:0038033 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway
GO:0038083 peptidyl-tyrosine autophosphorylation
GO:0038084 vascular endothelial growth factor signaling pathway
GO:0038089 positive regulation of cell migration by vascular endothelial growth factor signaling pathway
GO:0040017 positive regulation of locomotion
GO:0042391 regulation of membrane potential
GO:0043062 extracellular structure organization
GO:0043410 positive regulation of MAPK cascade
GO:0043534 blood vessel endothelial cell migration
GO:0043542 endothelial cell migration
GO:0044089 positive regulation of cellular component biogenesis
GO:0045216 cell-cell junction organization
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045785 positive regulation of cell adhesion
GO:0046777 protein autophosphorylation
GO:0048010 vascular endothelial growth factor receptor signaling pathway
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048041 focal adhesion assembly
GO:0048514 blood vessel morphogenesis
GO:0048568 embryonic organ development
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050918 positive chemotaxis
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0050926 regulation of positive chemotaxis
GO:0050927 positive regulation of positive chemotaxis
GO:0051272 positive regulation of cellular component movement
GO:0051767 nitric-oxide synthase biosynthetic process
GO:0051769 regulation of nitric-oxide synthase biosynthetic process
GO:0051770 positive regulation of nitric-oxide synthase biosynthetic process
GO:0051881 regulation of mitochondrial membrane potential
GO:0051882 mitochondrial depolarization
GO:0051893 regulation of focal adhesion assembly
GO:0051894 positive regulation of focal adhesion assembly
GO:0051899 membrane depolarization
GO:0051900 regulation of mitochondrial depolarization
GO:0051901 positive regulation of mitochondrial depolarization
GO:0060326 cell chemotaxis
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0072577 endothelial cell apoptotic process
GO:0090109 regulation of cell-substrate junction assembly
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090140 regulation of mitochondrial fission
GO:0090141 positive regulation of mitochondrial fission
GO:1901342 regulation of vasculature development
GO:1901888 regulation of cell junction assembly
GO:1901890 positive regulation of cell junction assembly
GO:1903391 regulation of adherens junction organization
GO:1903393 positive regulation of adherens junction organization
GO:1904018 positive regulation of vasculature development
GO:1904019 epithelial cell apoptotic process
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904036 negative regulation of epithelial cell apoptotic process
GO:1904181 positive regulation of membrane depolarization
GO:2000021 regulation of ion homeostasis
GO:2000147 positive regulation of cell motility
GO:2000351 regulation of endothelial cell apoptotic process
GO:2000352 negative regulation of endothelial cell apoptotic process
GO:2001026 regulation of endothelial cell chemotaxis
GO:2001028 positive regulation of endothelial cell chemotaxis
GO:2001212 regulation of vasculogenesis
GO:2001214 positive regulation of vasculogenesis
Molecular Function GO:0004713 protein tyrosine kinase activity
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0004716 receptor signaling protein tyrosine kinase activity
GO:0005021 vascular endothelial growth factor-activated receptor activity
GO:0005057 receptor signaling protein activity
GO:0005178 integrin binding
GO:0019199 transmembrane receptor protein kinase activity
GO:0019838 growth factor binding
GO:0031072 heat shock protein binding
GO:0050839 cell adhesion molecule binding
GO:0051879 Hsp90 protein binding
Cellular Component GO:0005769 early endosome
GO:0045121 membrane raft
GO:0097443 sorting endosome
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04060 Cytokine-cytokine receptor interaction
hsa04144 Endocytosis
hsa04151 PI3K-Akt signaling pathway
hsa04370 VEGF signaling pathway
hsa04510 Focal adhesion
Reactome R-HSA-422475: Axon guidance
R-HSA-1266738: Developmental Biology
R-HSA-2682334: EPH-Ephrin signaling
R-HSA-3928663: EPHA-mediated growth cone collapse
R-HSA-1474244: Extracellular matrix organization
R-HSA-216083: Integrin cell surface interactions
R-HSA-194306: Neurophilin interactions with VEGF and VEGFR
R-HSA-162582: Signal Transduction
R-HSA-194138: Signaling by VEGF
R-HSA-195399: VEGF binds to VEGFR leading to receptor dimerization
R-HSA-194313: VEGF ligand-receptor interactions
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
Summary
SymbolKDR
Namekinase insert domain receptor
Aliases FLK1; VEGFR; VEGFR2; CD309; vascular endothelial growth factor receptor 2; fetal liver kinase 1; kinase inse ......
Chromosomal Location4q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KDR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between KDR and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
18363997Melanoma; Colon Carcinoma; Breast Carcinoma; Lung carcinomaPromote immunity (T cell function); essential for immunotherapyFour novel oral DNA vaccines provide protection against melanoma, colon, breast, and lung carcinoma in mouse models. Vaccines are delivered by attenuated Salmonella typhimurium to secondary lymphoid organs and respectively target vascular endothelial growth factor receptor-2, transcription factor Fos-related antigen-1, anti-apoptosis protein survivin and Legumain, an asparaginyl endopeptidase specifically overexpressed on tumor-associated macrophages (TAMs) in the tumor microenvironment (TME). Key mechanisms induced by these DNA vaccines include efficient suppression of angiogenesis in the tumor vasculature and marked activation of cytotoxic T cells, natural killer cells, and antigen-presenting dendritic cells.
19380802Breast carcinomaPromote immunityTargeting a central cell type involved in angiogenesis, endothelial cells, we immunized against host vascular endothelial growth factor receptor 2 to fight the growth of Her-2/neu(+) breast tumors. Using the bacterial vector, Listeria monocytogenes (Lm), we fused polypeptides from the mouse vascular endothelial growth factor receptor 2 molecule (fetal liver kinase-1) to the microbial adjuvant, listeriolysin-O, and used Lm to deliver the Ags and elicit potent antitumor CTL responses.
23649001Breast CarcinomaInhibit immunityTEMs from breast tumors are able to suppress tumor-specific immune responses. Importantly, proangiogenic and suppressive functions of TEMs are similarly driven by TIE-2 and VEGFR kinase activity.
23633494MelanomaPromote immunity (infiltration); Promote immunity (T cell function); essential for immunotherapySimultaneous transfer of genetically engineered syngeneic T cells expressing a chimeric antigen receptor targeting the VEGF receptor-2 (VEGFR2; KDR) that is overexpressed on tumor vasculature and T-cells specific for the tumor antigens gp100 (PMEL), TRP-1 (TYRP1), or TRP-2 (DCT) synergistically eradicated established B16 melanoma tumors in mice and dramatically increased the tumor-free survival of mice compared with treatment with either cell type alone or T cells coexpressing these two targeting molecules. The synergistic antitumor response was accompanied by a significant increase in the infiltration and expansion and/or persistence of the adoptively transferred tumor antigen-specific T cells in the tumor microenvironment and thus enhanced their antitumor potency.
24965046GliomaPromote immunityThe inhibition of immune cell recruitment and tumor regression by anti-angiogenic receptor tyrosine kinase inhibitors, previously observed in several brain tumor models, was recapitulated in the 9L tumor model with the VEGFR2-specific inhibitory monoclonal antibody DC101 (p < 0.01), implicating VEGFR2 signaling as an essential step in metronomic cyclophosphamide-stimulated immune cell recruitment.
Summary
SymbolKDR
Namekinase insert domain receptor
Aliases FLK1; VEGFR; VEGFR2; CD309; vascular endothelial growth factor receptor 2; fetal liver kinase 1; kinase inse ......
Chromosomal Location4q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KDR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolKDR
Namekinase insert domain receptor
Aliases FLK1; VEGFR; VEGFR2; CD309; vascular endothelial growth factor receptor 2; fetal liver kinase 1; kinase inse ......
Chromosomal Location4q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KDR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5020.186
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6690.592
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3810.693
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0310.933
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.410.82
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5840.787
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5410.199
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.50.725
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.610.695
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.5550.351
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 283.1830.161
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1360.204
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KDR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277322.25.516.70.0222
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275922.26.815.40.0651
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21171917.61.41
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.427.3-11.90.63
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.118.8-7.71
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592022.2-2.21
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKDR
Namekinase insert domain receptor
Aliases FLK1; VEGFR; VEGFR2; CD309; vascular endothelial growth factor receptor 2; fetal liver kinase 1; kinase inse ......
Chromosomal Location4q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KDR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKDR
Namekinase insert domain receptor
Aliases FLK1; VEGFR; VEGFR2; CD309; vascular endothelial growth factor receptor 2; fetal liver kinase 1; kinase inse ......
Chromosomal Location4q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KDR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KDR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKDR
Namekinase insert domain receptor
Aliases FLK1; VEGFR; VEGFR2; CD309; vascular endothelial growth factor receptor 2; fetal liver kinase 1; kinase inse ......
Chromosomal Location4q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KDR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKDR
Namekinase insert domain receptor
Aliases FLK1; VEGFR; VEGFR2; CD309; vascular endothelial growth factor receptor 2; fetal liver kinase 1; kinase inse ......
Chromosomal Location4q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KDR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKDR
Namekinase insert domain receptor
Aliases FLK1; VEGFR; VEGFR2; CD309; vascular endothelial growth factor receptor 2; fetal liver kinase 1; kinase inse ......
Chromosomal Location4q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KDR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKDR
Namekinase insert domain receptor
Aliases FLK1; VEGFR; VEGFR2; CD309; vascular endothelial growth factor receptor 2; fetal liver kinase 1; kinase inse ......
Chromosomal Location4q11-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KDR collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting KDR.
ID Name Drug Type Targets #Targets
DB00398SorafenibSmall MoleculeBRAF, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET10
DB01268SunitinibSmall MoleculeCSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB8
DB04727N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FURO[2,3-D]PYRIMIDIN-5-YL}PHENYL)-N'-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]UREASmall MoleculeKDR1
DB04849CediranibSmall MoleculeKDR1
DB04879VatalanibSmall MoleculeFLT1, FLT4, KDR3
DB05014XL999Small MoleculeFGFR1, FGFR3, FLT3, KDR, PDGFRB5
DB05075TG-100801Small MoleculeCSK, FLT1, FLT4, KDR4
DB05146XL820Small MoleculeKDR, KIT, PDGFRA, PDGFRB4
DB05198CYC116Small MoleculeAURKA, KDR2
DB05578RamucirumabBiotechKDR1
DB05931PegdinetanibSmall MoleculeKDR1
DB05984RAF-265Small MoleculeBRAF, KDR2
DB06080ABT-869Small MoleculeCSF1R, FLT1, FLT3, FLT4, KDR, KIT6
DB06101IMC-1C11BiotechFLT1, FLT4, KDR3
DB06436SemaxanibSmall MoleculeKDR1
DB06589PazopanibSmall MoleculeFGF1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B310
DB06595MidostaurinSmall MoleculeFLT3, KDR, KIT, PDGFRA, PDGFRB, PRKCA6
DB06626AxitinibSmall MoleculeFLT1, FLT4, KDR3
DB069384-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamideSmall MoleculeKDR1
DB07183N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamideSmall MoleculeKDR1
DB07274N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamideSmall MoleculeKDR1
DB073266-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamideSmall MoleculeKDR1
DB07333N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDESmall MoleculeKDR1
DB07334N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINESmall MoleculeKDR1
DB075143-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-oneSmall MoleculeKDR1
DB075283-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-oneSmall MoleculeKDR1
DB07537N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamideSmall MoleculeKDR1
DB08042N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamineSmall MoleculeKDR1
DB08519N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamineSmall MoleculeKDR1
DB08875CabozantinibSmall MoleculeKDR, MET, RET3
DB08896RegorafenibSmall MoleculeABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, ......18
DB08901PonatinibSmall MoleculeABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, P ......15
DB09078LenvatinibSmall MoleculeFGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, KIT8
DB09079NintedanibSmall MoleculeFGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, LCK, LYN, SRC10
DB12307ForetinibSmall MoleculeHGF, KDR2